SecBot SecBot
Insider Buy ·Filed Aug 17, 2026

KURA

Kura Oncology, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-354201
Insider cluster: 1 insiders, $1.1M total
Actionable Insight ▲ Bullish

CEO's open-market purchase at $11.12 signals strong insider conviction ahead of potential upcoming catalysts (pipeline data, regulatory milestones). Monitor for additional insider buying or pipeline announcements in the coming weeks.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.33
T+0 close · Aug 17, 2026 · via day close
Latest settled
−38.60%
T+60 · $7.57
Vs SPY
−36.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $12.33entry
  2. T+1 · 3mo ago +1.62%α +1.41% · $12.53
  3. T+5 · 3mo ago +10.22%α +10.42% · $13.59
  4. T+20 · 2mo ago −7.83%α −6.84% · $11.37
  5. T+60 · 6d ago −38.60%α −36.56% · $7.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology CEO Troy Wilson purchased 100,000 shares worth $1.11M on the open market at $11.12/share, representing a material insider conviction buy. This is a strong standalone bullish signal from the highest-ranking insider, particularly notable given the company's $966M market cap and the CEO's direct cash deployment.

Key Financial Metrics

Direction
buying
Total Value
$1.1M
Insiders
1

Key Facts

  • CEO Troy Wilson purchased 100,000 shares at $11.12/share for total consideration of $1,112,000
  • Purchase represents approximately 0.12% of KURA's $966M market cap
  • This is the only insider trade in the past 7 days and the only buy in the past 30 days
  • CEO is the highest-ranking insider, making this a conviction buy signal

Financial Impact

CEO invested $1.11M of personal capital at $11.12/share, representing ~0.12% of market cap

insider ownershipmanagement alignment

Risk Factors

  • Single insider trade may not reflect broader company outlook
  • Biotech sector volatility could overshadow insider signal
  • No specific catalyst disclosed alongside the purchase

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001193125-26-354201

Track record

29 reports on KURA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 5h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026